UBX-103 / Ubix Therap, Yuhan Corp - LARVOL DELTA

Yuhan secures global rights to Ubix Therapeutics' prostate cancer treatment (Korea Biomedical Review) - "Ubix Therapeutics, a Korean biotech company, said it has entered into a licensing agreement with Yuhan Corp. to develop and commercialize its prostate cancer treatment candidate, UBX-103...Under the agreement, Yuhan will gain exclusive global rights to develop and commercialize UBX-103, a novel therapeutic targeting androgen receptor (AR) degradation....Ubix is set to receive an upfront payment of 5 billion won ($3.6 million) and could earn up to 150 billion won in development and sales milestones. Additionally, Ubix will receive royalties based on future sales and a portion of the revenues if Yuhan licenses the product to a third party."

Licensing / partnership • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Ubik Therapeutics, Korea's first TPD clinical trial… Announced at the American AACR [Google translation] (Hankyung) - "Ubix Therapeutics will present non-clinical research results and phase 1 clinical trial plans for UBX-303-1, a new drug candidate for blood cancer treatment, at the American Association for Cancer Research (AACR), which will be held in San Diego from the 5th to the 10th of next month (local time). It was announced on the 7th that it would announce....Ubix Therapeutics received approval for the clinical trial designation (IND) for UBX-303-1 from the U.S. Food and Drug Administration (FDA) at the end of last year and is planning to begin recruiting patients for clinical trials within the first half of this year....In addition to UBX-303-1, major pipelines include UBX-103, a prostate cancer treatment candidate undergoing non-clinical development with the goal of starting clinical trials in the first half of 2025..."

New P1 trial • New trial • Preclinical • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor

Ubik Therapeutics selected for KDDF non-clinical project for prostate cancer treatment [Google translation] (HIT News) - "Ubix Therapeutics...has been selected by the National New Drug Development Foundation (Director Muk Hyeon-sang, KDDF) ​​for the project ‘ UBX-103 (development code name)’, an androgen receptor (AR) degrader indicated for castration-resistant prostate cancer announced on the 21st that it was selected as a non-clinical project for the 2nd National New Drug Development Project in 2023 and signed an agreement. Ubix Therapeutics will receive development costs for UBX-103 from KDDF for two years until May 2025. Through this, the company announced that it plans to apply for a phase 1 clinical trial (IND) in the first half of 2025 by performing GLP toxicity testing and producing raw materials and finished products for non-clinical and clinical trials....In addition, it was confirmed that in a castration-resistant prostate cancer mouse model, it showed more than three times the cancer growth inhibition effect compared to ARV-110."

IND • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor